Clinical trials: Relapsed or Refractory Multiple Myeloma (MM)
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously…
- Trial name
- NCT02992483
- Testing
- MIK665
- Where
- 8 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma in Relapse
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
Primary objective of the study is the determination of the maximum tolerated dose (MTD) of Vorinostat (V), given in combination with fixed doses of Doxorubicin (D), Bortezomib (B) and Dexamethasone (D).
- Trial name
- VBDD (NCT01394354)
- Testing
- Vorinostat, Bortezomib, Doxorubicin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- University Hospital Freiburg
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
- Trial name
- NCT06515262
- Testing
- Anti-BCMA-GPRC5D CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Multiple Myeloma
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
The investigators hypothesize that conformal radiation will allow the administration of higher doses of external beam radiation to marrow based malignancies than total body irradiation (TBI)without increasing the toxicity to…
- Trial name
- TMI-ASCT (NCT00800059)
- Testing
- Total Marrow Irradiation
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- Ottawa Hospital Research Institute
Multiple Myeloma
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
- Trial name
- NCT03539744
- Testing
- Pomalidomide, Dexamethasone, Venetoclax
- Where
- 180 sites in United States, Australia and 18 more
- Volunteers
- 265 people
- Sponsor
- AbbVie
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Multiple Myeloma, Plasma Cell Leukemia
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe…
- Trial name
- NCT06045091
- Testing
- Human BCMA targeted CAR-NK cells injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have…
- Trial name
- NCT02431208
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM).
- Trial name
- Prime REMIX (NCT07725406)
- Testing
- Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Multiple Myeloma
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM.
- Trial name
- NCT04412889
- Testing
- BCMA/CD19 dual-target CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Multiple Myeloma
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in…
- Trial name
- NCT07409246
- Testing
- ABBV-438
- Where
- 14 sites in United States, China and 2 more
- Volunteers
- 127 people
- Sponsor
- AbbVie
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to…
- Trial name
- NCT00648739
- Testing
- Samalizumab
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Relapsed or Refractory Multiple Myeloma
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05052970
- Testing
- Mitoxantrone Hydrochloride Liposome injection, Bortezomib for Injection, Dexamethasone Acetate Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma in Relapse, Multiple Myeloma (MM)
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07735546
- Testing
- UB-VV500, Rapamycin (sirolimus)
- Volunteers
- 100 people
- Sponsor
- Umoja Biopharma
Multiple Myeloma
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines…
- Trial name
- NCT02899052
- Testing
- Carfilzomib, Venetoclax, Dexamethasone
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Multiple Myeloma
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and…
- Trial name
- EXCALIBER-RRMM (NCT04975997)
- Testing
- Dexamethasone, Daratumumab, Bortezomib
- Where
- 259 sites in United States, Argentina and 29 more
- Volunteers
- 939 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals